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Original Article
Ductal Carcinoma in Situ (DCIS) in Karachi
Naila Kayani, Yasmin Bhurgri*
Department of Pathology, Aga Khan University Hospital*, Karachi Cancer Registry*, Sindh Medical College*, Karachi.

Abstract
Objective: To study the frequency of ductal carcinoma in situ (DCIS) in a large pathology series. DCIS is a proliferation of non-invasive, malignant epithelial cells within the ductolobular system of the breast. It is a heterogeneous entity with several morphologic variants that differ in gross appearance, growth pattern, cytologic features,
mammography, and malignant potential.
Methods: The data of The Aga Khan University' Pathology Department, diagnosed on the basis of histopathology, during a 6-year period (1st January 1998 to 31st December 2003) was reviewed, all cases of DCIS studied,
and data was analyzed with the help of analytical software SPSS.
Results: Thirty-eight cases of DCIS were reported to the Aga Khan University Pathology Department, during a
6-year period (1998 to 2003), comprising approximately 1% of all breast cancers reported to the unit in the same
period. The mean age of the patients at diagnosis was 48.95 years (CI 95% 44.6; 53.3). Approximately half the
cases occurred in the 45-54 year age group (figure 1). Two cases (5.3%) were recurrences with previous lumpectomy scars. Comedo necrosis was observed in five (13.2%) cases, whereas 33 (86.8%) cases were non-comedo type. The clinical presentation was a palpable mass (92.1%), nipple discharge (5.3 %) or clinically occult
lesions diagnosed on mammography (2.6%). Approximately half the patients presented with a grade 2 disease.
Atypical ductal hyperplasia was observed in a third of the cases, predominantly associated with a grade 1 and 2
disease. The estrogen and progesterone receptor status was studied in 12 (31.6%) cases. Estrogen positivity
was observed in 11 (91.7%) cases and progesterone positivity in 7 (58.3%) cases. Microcalcification was
observed in four (10.6%) cases.
Conclusion: The cases reported in this study are the indolent grade 1 or 2 cases with a non-comedo pattern,
and a positive estrogen and progesterone receptor status. If untreated, only 40% of these innocuous forms of
DCIS become invasive over a time span of approximately 25-30 years. In Pakistan we are missing the more
aggressive forms of DCIS which have a shorter transition to invasive carcinoma (JPMA 55:199;2005).

Introduction
Ductal Carcinoma In Situ (DCIS) is a proliferation
of malignant epithelial cells within the ductolobular system
of the breast that do not show light microscopic evidence of
invasion through the basement membrane into the surrounding stroma. DCIS is a heterogeneous entity with several
morphologic variants that differ in gross appearance,
growth pattern, cytologic features, appearance on mammography, and malignant potential. It is a part of a spectrum of
proliferative ductal lesions of the breast that extend from
epithelial hyperplasia without atypia to microinvasive carcinoma.
There are various classification schemes for DCIS,
the simplest classifies it into two major subtypes based on
the presence or absence of comedo necrosis.1-4 There are
several other classifications based on histological structure,
nuclear grade, comedo-type necrosis, cytonuclear differentiation, or various combinations of these factors. The optimal classification scheme remains controversial. Nuclear
grade, comedo-type necrosis, tumour size, and the width of
the tumour margin are all important predictors of the probability of local recurrence after breast conservation treat-

ment for DCIS.5-12 Nuclear grade and necrosis, are the basis
of the Van Nuys classification.6
Comedo necrosis type of DCIS is diagnosed when at
least one duct in the breast is filled and expanded by large,
markedly atypical cells and has abundant central luminal
necrosis. The partially calcified necrotic material is recognized on mammography as linear and branching calcifications. Prominent periductal fibrosis may render the lesion
clinically palpable, and the resulting distortion of breast
parenchyma presents some difficulty in excluding microinvasion. Noncomedo necrosis type includes the cribriform,
micropapillary, and solid types, with combinations of the
various histologic patterns. Necrosis if present, is less
prominent than in the comedo necrosis type and not as
prone to calcification. Differentiation of the noncomedo
necrosis type from atypical ductal hyperplasia may be difficult.13-15

Methods
The data of The Aga Khan University Pathology
Department, diagnosed on the basis of histopathology, during a 6-year period (1st January 1998 to 31st December

2003) was reviewed and studied. The demographic
details of the registered pathology data were precise and
complete. Items such as age, sex, name, address, telephone
numbers and nature of surgery were well recorded at the
reception counter. A single medical registration number was
given to each in-patient and different specimens of the
patient given separate sub-identification numbers and data
updated. All cancer cases, both the in-patient and the outpatients were also given a specific cancer registration number
and information updated with subsequent visits. It was thus
possible to recognize duplicate examinations of the same
patient. This required a well-trained staff available at all the
59 collection points of this University lab, throughout the
country and also of the registration staff at the main lab.
Awareness of the legal and academic requirements of accuracy of demographic data was a part of the training of the
collection staff. Validity checks and random retrace of cases
was conducted for follow-up and for confirmation of the
information recorded.
Internal and external quality checks were used for
diagnostic pathology as well as the pathology-based cancer
data. External quality assurances for diagnostic pathology
were maintained by the College of American Pathologists
(CAP) surveys. Internal quality control and standardization
of the diagnosed data was maintained by using prompt and
adequate fixation, grossing as per standard protocol and
using histochemical stains, immunohistochemical techniques and biological markers as and when required.
ISO 9002 certified the clinical pathology lab in
1999. Consensus diagnosis of all doubtful cases at the daily
departmental consultation conferences improved the quality
of diagnosed data. Assistance and technical help of Armed
Forces Institute of Pathology (AFIP) Washington DC was
taken for confirmation of challenging cases.
Immunohistochemistry was used for malignancies, which
necessitated cellular typing and sub-typing. Computerized
and manual validity checks for the cancer data were also
performed as per recommendations of International Agency
for Research on Cancer (IARC) and International
Association of Cancer Registries (IACR).16,17 This involved
factors influencing comparability i.e. classification and coding. The data are classified using the International
Classification of Diseases-Oncology (ICD-O2) and computerized using a customized version of Canreg-3.18 This software includes facilities for detecting duplicate registrations
of the same cancer and for performing checks on the validity of the entered data. The data was re-checked with the
help of the AKUH laboratory database using SNOMED
coding and the Canreg-3 database of the Karachi Cancer
Registry.19 The variables that were recorded were the hospital patient-number date of incidence, name, age, sex,
address, topography, morphology, grading and staging. The

data was analyzed with the help of analytical software EPIInfo incorporated into Canreg-3 and SPSS database.

Results
Thirty-eight cases of DCIS were reported to the Aga
Khan University Pathology Department, during a 6-year
period (1998 to 2003). This comprises approximately 1% of
all breast cancers reported to the unit in the same period.
The mean age of the patients at diagnosis was 48.95 years
(CI 95% 44.6; 53.3). Approximately half the cases occurred
in the 45-54 year age group (Figure). The left breast was
involved in 15 (39.5%), the right breast in nine (23.7%) and
both breasts 2 (5.3%) cases. Laterality was not known for 12
(31.5%) cases. Two cases (5.3%) were recurrences with previous lumpectomy scars.
Comedo necrosis was observed in five (13.2%)
cases, whereas 33 (86.8%) cases were non-comedo type. In
the latter the spectrum of histological architecture was cribriform in 7 (21.0%), solid in 2 (6.3%), micropapillary in 8
(24.1%), and combinations in 16 (48.5%) cases. Non-comedo necrosis was observed in 2 (5.3%) cases. The clinical
presentation was a palpable mass (92.1%), nipple discharge
(5.3%) or clinically occult lesions diagnosed on mammography (2.6%).
Approximately half the patients presented with a
grade 2 disease. (Table 1) Atypical ductal hyperplasia was
observed in a third of the cases, predominantly associated
with a grade 1 and 2 disease (Table 2). Fibrocystic disease
Table 1. Histological grade of DCIS at diagnosis.
Grade

Grade I

Frequency

Percent

Cumulative
percent

8

21.1

21.1

Grade II

16

42.1

63.2

Grade III

10

26.3

89.5

Unknown

4

10.5

100.0

Total

38

100.0

was observed in 13.2% of the cases.
The estrogen and progesterone receptor status was
studied in 12 (31.6%) cases. Estrogen positivity was
observed in 11 (91.7%) cases and progesterone positivity in
7 (58.3%) cases (Table 3). Microcalcification was observed
in 4 (10.6%) cases, 2 (5.3%) cases each associated with
comedo necrosis and non-comedo necrosis.

Discussion
In the developed countries, DCIS was a relatively

grade 2 disease. (Table 1) Atypical ductal hyperplasia was observed in a third of the cases, predominantly associated with a grade 1 and 2 disease (Table 2). Fibrocystic
disease was observed in 13.2% of the cases.
Table 2. Association of histological grade of DCIS with atypical
hyperplasia.
Grade

Atypical
hyperplasia

Percent

Grade I

6

54.6

54.6

Grade II

3

27.3

81.9

Grade III

2

18.1

100

11

100.0

Total

Cumulative
Percent

The estrogen and progesterone receptor status was
studied in 12 (31.6%) cases. Estrogen positivity was
observed in 11 (91.7%) cases and progesterone positivity in
7 (58.3%) cases (Table 3). Microcalcification was observed
in 4 (10.6%) cases, 2 (5.3%) cases each associated with
comedo necrosis and non-comedo necrosis.
Table 3. Estrogen-progesterone receptor status.
Status

Estrogen-Receptor

ProgesteroneReceptor

(# 12) %

(# 12) %

Weak +

50.0

0.0

Intermediate +

25.0

50.0

Strong +

16.7

8.3

Negative

8.3

41.7

Discussion
In the developed countries, DCIS was a relatively
uncommon disease, until recently, representing only about
1% of all newly diagnosed cases of breast cancer.20 The
presentation was a palpable mass or discharge from the nipple. In 1998, DCIS accounted for about 18% of all newlydiagnosed invasive plus noninvasive breast tumors in the
United States.21 In contrast during 1997, more than 36,000
new cases of DCIS, representing 17% of all new breast cancers, had been diagnosed.22 This figure has shown a dramatically increase, almost all the cases are diagnosed by mammography and are clinically occult. The frequency of DCIS
in Pakistan is low, to date approximately 1%, and drastically low in comparison to the present status of DCIS in developed countries.

In the US 92.0% of all newly diagnosed patients
with DCIS have non-palpable lesions.22 Ironically, in the
present series, 92.1% of DCIS presented with breast lumps
and a mere 2.6% were diagnosed on mammography. High
quality mammography is capable of finding a range of
asymptomatic non-invasive lesions that cannot be palpated.
These are often smaller, of lower nuclear grade, and show
much subtler changes.
The considerable effect of modern mammography
can be appreciated by the experience at the Breast Center in
Van Nuys. During the first three years of operation (197981), with only a single outdated mammography unit available and no full time radiologist, an average of five cases
were found each year, 16% of which were non-palpable and
detected mammographically. In 1982, with four new state of
the art mammography units and a full time radiologist specialising in mammography, the number of new cases
increased dramatically. Fifty-eight cases were diagnosed in
1997, 11 times the number found in the first year of operation.23
In the best scenario, the most common mammographic finding is microcalcification and this was observed
in a very insignificant (10.6%) number of cases in the present study. This calls for capacity building in terms of
machines and manpower, for the detection of the most
innocuous cases. Good mammography, is expensive,
requires state of art mammography machines and radiologists specialising in mammography capable of exceptional
attention to detail. The need for expert radiological interpretation cannot be overemphasized and is sadly deficient in
Pakistan.
The cases reported in this study are the largely indolent grade 1 or 2 cases with a non-comedo pattern, and associated atypical ductal hyperplasia. The estrogen and progesterone receptor status was studied in a third of the cases, the
estrogen status was positive in almost all these cases and
two thirds exhibited a progesterone positivity.
If untreated, these innocuous looking forms of DCIS
(low nuclear grade, small celled without necrosis, positive
estrogen and progesterone receptor status, and a negative cerbB2) may never cause a clinical problem. Only about 40%
of untreated low-grade lesions become invasive over a time
span of approximately 25-30 years.25
In Pakistan we are missing the more aggressive
forms of DCIS which have a shorter transition to invasive
carcinoma.This justifies the feasibility of breast screening
for the detection of DCIS in a low resource setting, atleast
in the high risk groups. Planning for appropriate capacity
building is necessary to provide affordable, readily available, state of art mammography.
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